Core Viewpoint - Abivax has enrolled the first patient in its Phase 2b ENHANCE-CD trial for obefazimod, targeting Crohn's disease, marking a significant advancement in treatment options for patients with moderately to severely active conditions [2][3]. Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that stabilize the immune response in chronic inflammatory diseases [6]. - The company's lead drug candidate, obefazimod, is currently in Phase 3 trials for ulcerative colitis and has shown positive results in previous studies [5][6]. Trial Design - The ENHANCE-CD trial consists of three phases: a 12-week induction phase, a 40-week maintenance phase, and a 48-week extension phase, aimed at evaluating the efficacy and safety of obefazimod compared to placebo [4]. - The primary objective of the 48-week extension phase is to assess the safety and tolerability of obefazimod in subjects who have previously shown inadequate response to conventional therapies [4]. Drug Information - Obefazimod is an orally administered small molecule that may enhance the expression of microRNA miR-124, with ongoing exploration for combination therapy opportunities in ulcerative colitis [5].
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease